First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus (Q21195757)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus |
scientific article |
Statements
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus (English)
Marcus Hompesch
Marcus
Hompesch
Anita Kapur
Robin O'Connor-Semmes
Elizabeth K Hussey
Robert L Dobbins
Wenli Tao
Glenn A Smith
Charles D James
Imao Mikoshiba
Derek J Nunez
1
0 references
13 May 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference